Is Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease?

Bax is a proapoptotic member of the Bcl‐2 family of proteins. It is believed to exert its action primarily by facilitating the release of cytochrome c from the mitochondrial intermembrane space into the cytosol, leading to caspase activation and cell death. Because alterations in mitochondrial respi...

Full description

Saved in:
Bibliographic Details
Published inJournal of neurochemistry Vol. 76; no. 6; pp. 1785 - 1793
Main Authors Hartmann, Andreas, Michel, Patrick P., Troadec, Jean‐Denis, Mouatt‐Prigent, Annick, Faucheux, Baptiste A., Ruberg, Merle, Agid, Yves, Hirsch, Etienne C.
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Science Ltd 01.03.2001
Blackwell
Subjects
Online AccessGet full text
ISSN0022-3042
1471-4159
DOI10.1046/j.1471-4159.2001.00160.x

Cover

Abstract Bax is a proapoptotic member of the Bcl‐2 family of proteins. It is believed to exert its action primarily by facilitating the release of cytochrome c from the mitochondrial intermembrane space into the cytosol, leading to caspase activation and cell death. Because alterations in mitochondrial respiratory function, caspase activation and cell death with morphologic features compatible with apoptosis have been observed post mortem in the brain of patients with Parkinson's disease, we tried to clarify the potential role of Bax in this process in an immunohistochemical study on normal and Parkinson's disease post‐mortem brain and primary mesencephalic cell cultures treated with MPP+. We found that Bax is expressed ubiquitously by dopaminergic (DA) neurons in post‐mortem brain of normal and Parkinson's disease subjects as well as in vitro. Using an antibody to Bax inserted into the outer mitochondrial membrane as an index of Bax activation, no significant differences were observed between control and Parkinson's disease subjects, regardless of the mesencephalic subregion analysed. However, in Parkinson's disease subjects, the percentage of Bax‐positive melanized SNpc neurons containing Lewy bodies, suggestive of DA neuronal suffering, was significantly higher than the overall percentage of Bax‐positive neurons among melanized neurons. Furthermore, all melanized SNpc neurons in Parkinson's disease subjects with activated caspase‐3 were also immunoreactive for Bax, suggesting that Bax anchored in the outer mitochondrial membrane of melanized SNpc neurons showing signs of neuronal suffering or apoptosis is increased compared with DA neurons that are apparently unaltered. Surprisingly, MPP+ treatment of tyrosine hydroxylase (TH)‐positive neurons in primary mesencephalic cultures did not cause redistribution of Bax, although cytochrome c was released from the mitochondria and nuclear condensation/fragmentation was induced. Taken together, these findings suggest that in the human pathology, Bax may be a cofactor in caspase activation, but our in vitro data fail to indicate a central role for Bax in apoptotic death of DA neurons in an experimental Parkinson's disease paradigm.
AbstractList Bax is a proapoptotic member of the Bcl‐2 family of proteins. It is believed to exert its action primarily by facilitating the release of cytochrome c from the mitochondrial intermembrane space into the cytosol, leading to caspase activation and cell death. Because alterations in mitochondrial respiratory function, caspase activation and cell death with morphologic features compatible with apoptosis have been observed post mortem in the brain of patients with Parkinson's disease, we tried to clarify the potential role of Bax in this process in an immunohistochemical study on normal and Parkinson's disease post‐mortem brain and primary mesencephalic cell cultures treated with MPP+. We found that Bax is expressed ubiquitously by dopaminergic (DA) neurons in post‐mortem brain of normal and Parkinson's disease subjects as well as in vitro. Using an antibody to Bax inserted into the outer mitochondrial membrane as an index of Bax activation, no significant differences were observed between control and Parkinson's disease subjects, regardless of the mesencephalic subregion analysed. However, in Parkinson's disease subjects, the percentage of Bax‐positive melanized SNpc neurons containing Lewy bodies, suggestive of DA neuronal suffering, was significantly higher than the overall percentage of Bax‐positive neurons among melanized neurons. Furthermore, all melanized SNpc neurons in Parkinson's disease subjects with activated caspase‐3 were also immunoreactive for Bax, suggesting that Bax anchored in the outer mitochondrial membrane of melanized SNpc neurons showing signs of neuronal suffering or apoptosis is increased compared with DA neurons that are apparently unaltered. Surprisingly, MPP+ treatment of tyrosine hydroxylase (TH)‐positive neurons in primary mesencephalic cultures did not cause redistribution of Bax, although cytochrome c was released from the mitochondria and nuclear condensation/fragmentation was induced. Taken together, these findings suggest that in the human pathology, Bax may be a cofactor in caspase activation, but our in vitro data fail to indicate a central role for Bax in apoptotic death of DA neurons in an experimental Parkinson's disease paradigm.
Bax is a proapoptotic member of the Bcl-2 family of proteins. It is believed to exert its action primarily by facilitating the release of cytochrome c from the mitochondrial intermembrane space into the cytosol, leading to caspase activation and cell death. Because alterations in mitochondrial respiratory function, caspase activation and cell death with morphologic features compatible with apoptosis have been observed post mortem in the brain of patients with Parkinson's disease, we tried to clarify the potential role of Bax in this process in an immunohistochemical study on normal and Parkinson's disease post-mortem brain and primary mesencephalic cell cultures treated with MPP(+). We found that Bax is expressed ubiquitously by dopaminergic (DA) neurons in post-mortem brain of normal and Parkinson's disease subjects as well as in vitro. Using an antibody to Bax inserted into the outer mitochondrial membrane as an index of Bax activation, no significant differences were observed between control and Parkinson's disease subjects, regardless of the mesencephalic subregion analysed. However, in Parkinson's disease subjects, the percentage of Bax-positive melanized SNpc neurons containing Lewy bodies, suggestive of DA neuronal suffering, was significantly higher than the overall percentage of Bax-positive neurons among melanized neurons. Furthermore, all melanized SNpc neurons in Parkinson's disease subjects with activated caspase-3 were also immunoreactive for Bax, suggesting that Bax anchored in the outer mitochondrial membrane of melanized SNpc neurons showing signs of neuronal suffering or apoptosis is increased compared with DA neurons that are apparently unaltered. Surprisingly, MPP(+) treatment of tyrosine hydroxylase (TH)-positive neurons in primary mesencephalic cultures did not cause redistribution of Bax, although cytochrome c was released from the mitochondria and nuclear condensation/fragmentation was induced. Taken together, these findings suggest that in the human pathology, Bax may be a cofactor in caspase activation, but our in vitro data fail to indicate a central role for Bax in apoptotic death of DA neurons in an experimental Parkinson's disease paradigm.Bax is a proapoptotic member of the Bcl-2 family of proteins. It is believed to exert its action primarily by facilitating the release of cytochrome c from the mitochondrial intermembrane space into the cytosol, leading to caspase activation and cell death. Because alterations in mitochondrial respiratory function, caspase activation and cell death with morphologic features compatible with apoptosis have been observed post mortem in the brain of patients with Parkinson's disease, we tried to clarify the potential role of Bax in this process in an immunohistochemical study on normal and Parkinson's disease post-mortem brain and primary mesencephalic cell cultures treated with MPP(+). We found that Bax is expressed ubiquitously by dopaminergic (DA) neurons in post-mortem brain of normal and Parkinson's disease subjects as well as in vitro. Using an antibody to Bax inserted into the outer mitochondrial membrane as an index of Bax activation, no significant differences were observed between control and Parkinson's disease subjects, regardless of the mesencephalic subregion analysed. However, in Parkinson's disease subjects, the percentage of Bax-positive melanized SNpc neurons containing Lewy bodies, suggestive of DA neuronal suffering, was significantly higher than the overall percentage of Bax-positive neurons among melanized neurons. Furthermore, all melanized SNpc neurons in Parkinson's disease subjects with activated caspase-3 were also immunoreactive for Bax, suggesting that Bax anchored in the outer mitochondrial membrane of melanized SNpc neurons showing signs of neuronal suffering or apoptosis is increased compared with DA neurons that are apparently unaltered. Surprisingly, MPP(+) treatment of tyrosine hydroxylase (TH)-positive neurons in primary mesencephalic cultures did not cause redistribution of Bax, although cytochrome c was released from the mitochondria and nuclear condensation/fragmentation was induced. Taken together, these findings suggest that in the human pathology, Bax may be a cofactor in caspase activation, but our in vitro data fail to indicate a central role for Bax in apoptotic death of DA neurons in an experimental Parkinson's disease paradigm.
Bax is a proapoptotic member of the Bcl‐2 family of proteins. It is believed to exert its action primarily by facilitating the release of cytochrome c from the mitochondrial intermembrane space into the cytosol, leading to caspase activation and cell death. Because alterations in mitochondrial respiratory function, caspase activation and cell death with morphologic features compatible with apoptosis have been observed post mortem in the brain of patients with Parkinson's disease, we tried to clarify the potential role of Bax in this process in an immunohistochemical study on normal and Parkinson's disease post‐mortem brain and primary mesencephalic cell cultures treated with MPP + . We found that Bax is expressed ubiquitously by dopaminergic (DA) neurons in post‐mortem brain of normal and Parkinson's disease subjects as well as in vitro . Using an antibody to Bax inserted into the outer mitochondrial membrane as an index of Bax activation, no significant differences were observed between control and Parkinson's disease subjects, regardless of the mesencephalic subregion analysed. However, in Parkinson's disease subjects, the percentage of Bax‐positive melanized SNpc neurons containing Lewy bodies, suggestive of DA neuronal suffering, was significantly higher than the overall percentage of Bax‐positive neurons among melanized neurons. Furthermore, all melanized SNpc neurons in Parkinson's disease subjects with activated caspase‐3 were also immunoreactive for Bax, suggesting that Bax anchored in the outer mitochondrial membrane of melanized SNpc neurons showing signs of neuronal suffering or apoptosis is increased compared with DA neurons that are apparently unaltered. Surprisingly, MPP + treatment of tyrosine hydroxylase (TH)‐positive neurons in primary mesencephalic cultures did not cause redistribution of Bax, although cytochrome c was released from the mitochondria and nuclear condensation/fragmentation was induced. Taken together, these findings suggest that in the human pathology, Bax may be a cofactor in caspase activation, but our in vitro data fail to indicate a central role for Bax in apoptotic death of DA neurons in an experimental Parkinson's disease paradigm.
Bax is a proapoptotic member of the Bcl-2 family of proteins. It is believed to exert its action primarily by facilitating the release of cytochrome c from the mitochondrial intermembrane space into the cytosol, leading to caspase activation and cell death. Because alterations in mitochondrial respiratory function, caspase activation and cell death with morphologic features compatible with apoptosis have been observed post mortem in the brain of patients with Parkinson's disease, we tried to clarify the potential role of Bax in this process in an immunohistochemical study on normal and Parkinson's disease post-mortem brain and primary mesencephalic cell cultures treated with MPP super(+). We found that Bax is expressed ubiquitously by dopaminergic (DA) neurons in post-mortem brain of normal and Parkinson's disease subjects as well as in vitro. Using an antibody to Bax inserted into the outer mitochondrial membrane as an index of Bax activation, no significant differences were observed between control and Parkinson's disease subjects, regardless of the mesencephalic subregion analysed. However, in Parkinson's disease subjects, the percentage of Bax-positive melanized SNpc neurons containing Lewy bodies, suggestive of DA neuronal suffering, was significantly higher than the overall percentage of Bax-positive neurons among melanized neurons. Furthermore, all melanized SNpc neurons in Parkinson's disease subjects with activated caspase-3 were also immunoreactive for Bax, suggesting that Bax anchored in the outer mitochondrial membrane of melanized SNpc neurons showing signs of neuronal suffering or apoptosis is increased compared with DA neurons that are apparently unaltered. Surprisingly, MPP super(+) treatment of tyrosine hydroxylase (TH)-positive neurons in primary mesencephalic cultures did not cause redistribution of Bax, although cytochrome c was released from the mitochondria and nuclear condensation/fragmentation was induced. Taken together, these findings suggest that in the human pathology, Bax may be a cofactor in caspase activation, but our in vitro data fail to indicate a central role for Bax in apoptotic death of DA neurons in an experimental Parkinson's disease paradigm.
Author Mouatt‐Prigent, Annick
Troadec, Jean‐Denis
Faucheux, Baptiste A.
Michel, Patrick P.
Agid, Yves
Hirsch, Etienne C.
Hartmann, Andreas
Ruberg, Merle
Author_xml – sequence: 1
  givenname: Andreas
  surname: Hartmann
  fullname: Hartmann, Andreas
– sequence: 2
  givenname: Patrick P.
  surname: Michel
  fullname: Michel, Patrick P.
– sequence: 3
  givenname: Jean‐Denis
  surname: Troadec
  fullname: Troadec, Jean‐Denis
– sequence: 4
  givenname: Annick
  surname: Mouatt‐Prigent
  fullname: Mouatt‐Prigent, Annick
– sequence: 5
  givenname: Baptiste A.
  surname: Faucheux
  fullname: Faucheux, Baptiste A.
– sequence: 6
  givenname: Merle
  surname: Ruberg
  fullname: Ruberg, Merle
– sequence: 7
  givenname: Yves
  surname: Agid
  fullname: Agid, Yves
– sequence: 8
  givenname: Etienne C.
  surname: Hirsch
  fullname: Hirsch, Etienne C.
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1114763$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/11259496$$D View this record in MEDLINE/PubMed
BookMark eNqNkc1u1DAURi1URKeFV0BeIFgl2E7inwUgGAFtVQELWFs3jkM9JHZqe8T07UmYaYW6KQvLln3ud617TtCRD94ihCkpKan5601Ja0GLmjaqZITQcl6clLtHaHX3cIRWhDBWVKRmx-gkpc0C1Zw-QceUskbViq9Qe57wB9hhwKPLwVwF30UHAx5t5yCHiJ3HMIUph-wM7izkKxx63IUJRudt_DnferuNwacF_Qbxl_Mp-FcJdy5ZSPbdU_S4hyHZZ4f9FP349PH7-qy4_Pr5fP3-sjBNTUmhBDSk6wlXVSXJ_LtWSd5JJWnHWE9axmrBa6qUEKwjFQhTib6yDeVGSdWK6hS93OdOMVxvbcp6dMnYYQBvwzZpwZWUipMHQSpko0QjZ_D5Ady280D0FN0I8Ubfjm8GXhwASAaGPoI3Lv3DzTZ4NWNv95iJIaVoe21chuyCzxHcoCnRi1a90Ys9vdjTi1b9V6vezQHyXsBdi4dL3-xLf7vB3vx3nb74sl5O1R-jpbdR
CODEN JONRA9
CitedBy_id crossref_primary_10_1016_j_ejphar_2020_173815
crossref_primary_10_4103_0366_6999_218025
crossref_primary_10_1007_s00702_009_0240_y
crossref_primary_10_1089_ars_2011_4074
crossref_primary_10_1111_j_1471_4159_2007_05115_x
crossref_primary_10_1007_s11064_008_9876_5
crossref_primary_10_1016_j_bcp_2004_02_007
crossref_primary_10_1113_JP279791
crossref_primary_10_1046_j_1471_4159_2003_01520_x
crossref_primary_10_1016_j_bbadis_2009_09_004
crossref_primary_10_1016_j_ejcb_2008_03_003
crossref_primary_10_2174_1573401314666180503153444
crossref_primary_10_1016_S0006_8993_01_03360_1
crossref_primary_10_1016_j_expneurol_2005_04_011
crossref_primary_10_1016_j_neuint_2024_105902
crossref_primary_10_1021_acschemneuro_8b00356
crossref_primary_10_1038_s41531_023_00453_9
crossref_primary_10_1186_s40035_021_00278_7
crossref_primary_10_1016_j_neuroscience_2013_01_050
crossref_primary_10_1007_s10072_014_1700_1
crossref_primary_10_1016_j_bbadis_2013_09_007
crossref_primary_10_1016_j_phytochem_2010_08_015
crossref_primary_10_1016_S0929_6646_09_60380_6
crossref_primary_10_3390_ijms25021182
crossref_primary_10_3748_wjg_v25_i20_2463
crossref_primary_10_1186_1750_1326_7_40
crossref_primary_10_1038_srep25344
crossref_primary_10_1007_s00232_006_0015_4
crossref_primary_10_1007_s00702_007_0765_x
crossref_primary_10_1242_dev_01128
crossref_primary_10_1016_S0304_4165_02_00440_3
crossref_primary_10_1089_ars_2020_8229
crossref_primary_10_1007_s11696_018_0664_7
crossref_primary_10_1111_j_1527_3458_2005_tb00269_x
crossref_primary_10_1016_j_brainres_2009_10_036
crossref_primary_10_1111_jnc_13706
crossref_primary_10_1007_s12035_023_03849_z
crossref_primary_10_1016_S0896_6273_03_00568_3
crossref_primary_10_1016_j_neurol_2023_08_011
crossref_primary_10_1007_s12035_017_0741_x
crossref_primary_10_1016_j_neurobiolaging_2013_11_008
crossref_primary_10_3390_ijms22084045
crossref_primary_10_3390_ijms18051012
crossref_primary_10_1016_j_autneu_2007_02_002
crossref_primary_10_1089_rej_2012_1384
crossref_primary_10_1016_j_parkreldis_2008_04_026
crossref_primary_10_1016_j_pharmthera_2011_11_006
crossref_primary_10_1007_s11011_020_00546_x
crossref_primary_10_1073_pnas_0609874104
crossref_primary_10_3389_fneur_2018_00347
crossref_primary_10_1016_j_neuroscience_2013_01_007
crossref_primary_10_1038_nrn1100
crossref_primary_10_1016_j_cbi_2014_04_010
crossref_primary_10_1016_j_brainresbull_2003_08_005
crossref_primary_10_1016_j_parkreldis_2007_09_005
crossref_primary_10_1016_j_lfs_2015_11_019
crossref_primary_10_1111_neup_12592
crossref_primary_10_1002_jnr_10539
crossref_primary_10_1016_S1359_6446_03_03000_9
crossref_primary_10_3390_ijms19103082
crossref_primary_10_1016_S0278_5846_03_00025_3
crossref_primary_10_1007_s11033_022_07755_w
crossref_primary_10_1155_2012_131058
crossref_primary_10_1016_j_neulet_2010_10_002
crossref_primary_10_1038_gt_2008_88
crossref_primary_10_1007_s00441_004_0954_y
crossref_primary_10_1016_j_ijdevneu_2008_01_003
crossref_primary_10_1111_j_1471_4159_2007_04637_x
crossref_primary_10_1007_s12035_024_04111_w
crossref_primary_10_1016_S1566_2772_01_00021_4
crossref_primary_10_1111_j_1471_4159_2006_04291_x
crossref_primary_10_1016_j_bbadis_2009_08_013
crossref_primary_10_1007_s12035_016_0028_7
crossref_primary_10_1016_j_nbd_2009_10_011
crossref_primary_10_1038_s41419_019_2078_z
crossref_primary_10_1111_j_1471_4159_2010_07112_x
crossref_primary_10_1016_j_expneurol_2016_03_016
crossref_primary_10_1016_j_arr_2021_101263
crossref_primary_10_3233_MNM_180234
crossref_primary_10_4161_auto_28286
crossref_primary_10_31887_DCNS_2004_6_3_ahartmann
crossref_primary_10_1007_s00232_004_0654_2
crossref_primary_10_1111_j_1471_4159_2007_05028_x
crossref_primary_10_1016_j_molbrainres_2003_08_012
crossref_primary_10_1007_s12035_017_0855_1
crossref_primary_10_1111_jnc_13696
crossref_primary_10_1016_j_bcp_2004_09_018
crossref_primary_10_1186_s13041_016_0230_6
crossref_primary_10_1523_JNEUROSCI_4511_08_2008
crossref_primary_10_1016_j_cellsig_2010_10_020
crossref_primary_10_1111_j_1471_4159_2008_05604_x
crossref_primary_10_3390_antiox11112275
crossref_primary_10_1007_s12640_016_9631_7
crossref_primary_10_3390_biom10101421
crossref_primary_10_3390_ijms25189947
crossref_primary_10_1002_ana_10489
crossref_primary_10_1007_s11302_007_9073_z
crossref_primary_10_1016_j_pneurobio_2013_04_004
crossref_primary_10_3390_antiox10071069
crossref_primary_10_1007_s11064_008_9747_0
crossref_primary_10_1212_01_wnl_0000198511_09968_b3
Cites_doi 10.1523/JNEUROSCI.19-04-01284.1999
10.1016/0092-8674(93)90509-O
10.1083/jcb.144.5.891
10.1038/74994
10.1016/S0092-8674(00)80434-1
10.1016/0306-4522(96)00100-5
10.1073/pnas.100121097
10.1038/10556
10.1016/s0047-6374(99)00048-2
10.1016/0006-8993(92)91479-X
10.1002/(sici)1097-4547(19981015)54:2<214::aid-jnr9>3.3.co;2-q
10.1093/brain/114.5.2283
10.1002/1531-8257(199903)14:2<383::AID-MDS1037>3.0.CO;2-F
10.1083/jcb.139.5.1281
10.1016/s0306-4522(96)00545-3
10.1016/s0306-4522(98)00154-7
10.1046/j.1460-9568.2000.00966.x
10.1016/S0925-4439(98)00083-0
10.1046/j.1471-4159.1999.0722074.x
10.1016/S0896-6273(00)80173-7
10.1016/s0304-3940(97)00837-9
10.1073/pnas.040556597
10.1038/17135
10.1523/JNEUROSCI.15-10-06364.1995
10.1016/s0140-6736(99)05226-5
10.1016/s0306-4522(97)00640-4
10.1073/pnas.94.14.7531
10.1046/j.1471-4159.1996.67041633.x
10.1038/334345a0
10.1056/NEJM199810153391607
10.1046/j.1471-4159.1998.70062637.x
10.1038/sj.cdd.4400449
10.1073/pnas.94.8.3668
10.1002/ana.410440712
10.1016/s0169-328x(98)00318-0
10.1046/j.1471-4159.1994.63051987.x
10.1523/JNEUROSCI.19-17-07476.1999
10.1038/70237
10.1016/0304-3940(96)12323-5
10.1126/science.270.5233.96
10.1016/0304-3940(94)90271-2
10.1038/sj.onc.1202590
ContentType Journal Article
Copyright 2001 INIST-CNRS
Copyright_xml – notice: 2001 INIST-CNRS
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7TK
7X8
DOI 10.1046/j.1471-4159.2001.00160.x
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Neurosciences Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Neurosciences Abstracts
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
MEDLINE
CrossRef
Neurosciences Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
Chemistry
EISSN 1471-4159
EndPage 1793
ExternalDocumentID 11259496
1114763
10_1046_j_1471_4159_2001_00160_x
JNC0160
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-~X
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
1OB
1OC
24P
29L
2WC
31~
33P
36B
3SF
4.4
41~
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAYJJ
AAZKR
ABCQN
ABCUV
ABEML
ABIVO
ABLJU
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACFBH
ACGFO
ACGFS
ACGOD
ACGOF
ACIWK
ACMXC
ACNCT
ACPOU
ACPRK
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFPWT
AFRAH
AFWVQ
AFZJQ
AHBTC
AHEFC
AI.
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BAWUL
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DC6
DCZOG
DIK
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
E3Z
EBS
EJD
EMOBN
ESX
EX3
F00
F01
F04
F5P
FEDTE
FIJ
FUBAC
FZ0
G-S
G.N
GAKWD
GODZA
GX1
H.X
HF~
HGLYW
HH5
HVGLF
HZI
HZ~
IH2
IHE
IPNFZ
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MVM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
TEORI
TWZ
UB1
V8K
VH1
W8V
W99
WBKPD
WIH
WIJ
WIK
WIN
WNSPC
WOHZO
WOW
WQJ
WRC
WUP
WXI
WXSBR
WYISQ
X7M
XG1
XJT
YFH
YNH
YOC
YUY
ZGI
ZXP
ZZTAW
~IA
~KM
~WT
AAYXX
AEYWJ
AGYGG
CITATION
AAMMB
AEFGJ
AGHNM
AGQPQ
AGXDD
AIDQK
AIDYY
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
PKN
7TK
7X8
ID FETCH-LOGICAL-c5410-97a50df0693380949b986d8981d22f0b224764199772d03a7c37f3e516c989b73
IEDL.DBID DR2
ISSN 0022-3042
IngestDate Fri Jul 11 04:13:15 EDT 2025
Fri Jul 11 04:36:44 EDT 2025
Wed Feb 19 02:34:42 EST 2025
Mon Jul 21 09:13:46 EDT 2025
Thu Apr 24 22:54:32 EDT 2025
Tue Jul 01 02:14:29 EDT 2025
Wed Jan 22 16:29:31 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords Cytochrome c
Human
Nervous system diseases
Mitochondria
Central nervous system disease
Parkinson disease
Dopaminergic neuron
Degenerative disease
Cerebral disorder
Extrapyramidal syndrome
Apoptosis
Language English
License http://onlinelibrary.wiley.com/termsAndConditions#vor
CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5410-97a50df0693380949b986d8981d22f0b224764199772d03a7c37f3e516c989b73
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
OpenAccessLink https://onlinelibrary.wiley.com/doi/pdfdirect/10.1046/j.1471-4159.2001.00160.x
PMID 11259496
PQID 17859758
PQPubID 23462
PageCount 9
ParticipantIDs proquest_miscellaneous_76988960
proquest_miscellaneous_17859758
pubmed_primary_11259496
pascalfrancis_primary_1114763
crossref_citationtrail_10_1046_j_1471_4159_2001_00160_x
crossref_primary_10_1046_j_1471_4159_2001_00160_x
wiley_primary_10_1046_j_1471_4159_2001_00160_x_JNC0160
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate March 2001
PublicationDateYYYYMMDD 2001-03-01
PublicationDate_xml – month: 03
  year: 2001
  text: March 2001
PublicationDecade 2000
PublicationPlace Oxford, UK
PublicationPlace_xml – name: Oxford, UK
– name: Oxford
– name: England
PublicationTitle Journal of neurochemistry
PublicationTitleAlternate J Neurochem
PublicationYear 2001
Publisher Blackwell Science Ltd
Blackwell
Publisher_xml – name: Blackwell Science Ltd
– name: Blackwell
References 1991; 114
1997; 238
1997; 139
1996; 17
2000; 6
2000; 355
1994; 170
1995; 15
1998; 339
1996; 73
1999; 64
1999; 144
1999; 1
1998; 85
1998; 86
1999; 5
1994; 63
1998; 44
1995; 270
1996; 204
1997; 91
1998; 17
1997; 94
1997; 77
1999; 19
2000; 12
1999; 18
1992; 597
2000; 96
2000; 97
1999; 14
1993; 74
1988; 334
1998; 70
1999; 397
1999; 112
1999; 1453
1999; 72
1998; 5
1998; 54
1996; 67
e_1_2_7_6_1
e_1_2_7_5_1
e_1_2_7_4_1
e_1_2_7_3_1
e_1_2_7_9_1
e_1_2_7_8_1
e_1_2_7_7_1
e_1_2_7_19_1
e_1_2_7_18_1
e_1_2_7_17_1
e_1_2_7_16_1
e_1_2_7_40_1
e_1_2_7_2_1
e_1_2_7_15_1
e_1_2_7_41_1
e_1_2_7_14_1
e_1_2_7_42_1
e_1_2_7_13_1
e_1_2_7_43_1
e_1_2_7_12_1
e_1_2_7_44_1
e_1_2_7_11_1
e_1_2_7_10_1
e_1_2_7_26_1
e_1_2_7_27_1
e_1_2_7_29_1
e_1_2_7_30_1
e_1_2_7_25_1
e_1_2_7_31_1
e_1_2_7_24_1
e_1_2_7_32_1
e_1_2_7_23_1
e_1_2_7_33_1
e_1_2_7_22_1
Michel P. P. (e_1_2_7_28_1) 1999; 18
e_1_2_7_34_1
e_1_2_7_21_1
e_1_2_7_20_1
e_1_2_7_36_1
e_1_2_7_37_1
e_1_2_7_38_1
e_1_2_7_39_1
Putcha G. V. (e_1_2_7_35_1) 1999; 19
References_xml – volume: 597
  start-page: 233
  year: 1992
  end-page: 240
  article-title: The glutamate antagonist, MK‐801, does not prevent dopaminergic cell death induced by the 1‐methyl‐4‐phenylpyridinium ion (MPP+)
  publication-title: Brain Res.
– volume: 17
  start-page: 3401
  year: 1998
  end-page: 3415
  article-title: Role of hypoxia‐induced Bax translocation and cytochrome release in reoxygenation injury
  publication-title: Oncogene
– volume: 86
  start-page: 701
  year: 1998
  end-page: 707
  article-title: Peptide inhibitors of caspase‐3‐like proteases attenuate 1‐methyl‐4‐phenylpyridium‐induced toxicity of cultured fetal rat mesencephalic dopamine neurons
  publication-title: Neuroscience
– volume: 114
  start-page: 2283
  year: 1991
  end-page: 2301
  article-title: Ageing and Parkinson's disease: substantia nigra regional selectivity
  publication-title: Brain
– volume: 94
  start-page: 7531
  year: 1997
  end-page: 7536
  article-title: Nuclear translocation of NF‐kappaB is increased in dopaminergic neurons of patients with Parkinson disease
  publication-title: Proc. Natl Acad. Sci. USA
– volume: 17
  start-page: 1
  year: 1996
  end-page: 11
  article-title: BAX is required for neuronal death after trophic factor deprivation and during development
  publication-title: Neuron
– volume: 85
  start-page: 649
  year: 1998
  end-page: 651
  article-title: TUNEL‐positive cells in the substantia nigra of C57BL/6 mice after a single bolus of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine
  publication-title: Neuroscience
– volume: 72
  start-page: 2074
  year: 1999
  end-page: 2082
  article-title: Adenosine prevents the death of mesencephalic dopaminergic neurons by a mechanism that involves astrocytes
  publication-title: J. Neurochem.
– volume: 19
  start-page: 7476
  year: 1999
  end-page: 7485
  article-title: BAX translocation is a critical event in neuronal apoptosis: regulation by neuroprotectants, BCL‐2, and caspases
  publication-title: J. Neurosci.
– volume: 238
  start-page: 78
  year: 1997
  end-page: 80
  article-title: Bcl‐2 and Bax proteins in Lewy bodies from patients with Parkinson's disease and diffuse Lewy body disease
  publication-title: Neurosci. Lett.
– volume: 112
  start-page: 5
  year: 1999
  end-page: 25
  article-title: Influence of age on hypoxia/reoxygenation‐induced DNA fragmentation and bcl‐2, bcl‐xl, bax and fas in the rat heart and brain
  publication-title: Mech. Ageing Dev.
– volume: 44
  start-page: S72
  issue: Suppl. 1
  year: 1998
  end-page: S84
  article-title: Understanding cell death in Parkinson's disease
  publication-title: Ann. Neurol.
– volume: 1
  start-page: E209
  year: 1999
  end-page: E216
  article-title: Bcl‐2 proteins: regulators of apoptosis or of mitochondrial homeostasis?
  publication-title: Nat. Cell Biol.
– volume: 1453
  start-page: 49
  year: 1999
  end-page: 62
  article-title: The parkinsonian neurotoxin MPP opens the mitochondrial permeability transition pore and releases cytochrome in isolated mitochondria via an oxidative mechanism
  publication-title: Biochem. Biophys. Acta
– volume: 91
  start-page: 479
  year: 1997
  end-page: 489
  article-title: Cytochrome and dATP‐dependent formation of Apaf‐1/caspase‐9 complex initiates an apoptotic protease cascade
  publication-title: Cell
– volume: 67
  start-page: 1633
  year: 1996
  end-page: 1642
  article-title: Chronic activation of the cyclic AMP signaling pathway promotes development and long‐term survival of mesencephalic dopaminergic neurons
  publication-title: J. Neurochem.
– volume: 19
  start-page: 1284
  year: 1999
  end-page: 1293
  article-title: Distinct mechanisms underlie neurotoxin‐mediated cell death in cultured dopaminergic neurons
  publication-title: J. Neurosci.
– volume: 5
  start-page: 1004
  year: 1998
  end-page: 1016
  article-title: immunodetection of activated caspase‐3 in apoptotic neurons in the developing nervous system
  publication-title: Cell. Death Diff.
– volume: 54
  start-page: 214
  year: 1998
  end-page: 222
  article-title: Involvement of caspase‐like proteinases in apoptosis of neuronal PC12 cells and primary cultured microglia induced by 6‐hydroxydopamine
  publication-title: J. Neurosci. Res.
– volume: 397
  start-page: 441
  year: 1999
  end-page: 446
  article-title: Molecular characterization of mitochondrial apoptosis‐inducing factor
  publication-title: Nature
– volume: 94
  start-page: 3668
  year: 1997
  end-page: 3672
  article-title: Cytosol‐to‐membrane redistribution of Bax and Bcl‐X(L) during apoptosis
  publication-title: Proc. Natl Acad. Sci. USA
– volume: 5
  start-page: 832
  year: 1999
  end-page: 835
  article-title: Inhibition of virus‐induced neuronal apoptosis by Bax
  publication-title: Nat. Med.
– volume: 15
  start-page: 6364
  year: 1995
  end-page: 6376
  article-title: Upregulation of bax protein levels in neurons following cerebral ischemia
  publication-title: J. Neurosci.
– volume: 70
  start-page: 2637
  year: 1998
  end-page: 2640
  article-title: Caspases mediate 6‐hydoxydopamine‐induced apoptosis but not necrosis in PC12 cells
  publication-title: J. Neurochem.
– volume: 77
  start-page: 1037
  year: 1997
  end-page: 1048
  article-title: In situ detection of apoptotic nuclei in the substantia nigra compacta of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining
  publication-title: Neuroscience
– volume: 96
  start-page: 6161
  year: 2000
  end-page: 6166
  article-title: Mitochondrial and extramitochondrial apoptotic signaling pathways in cerebrocortical neurons
  publication-title: Proc. Natl Acad. Sci. USA
– volume: 74
  start-page: 609
  year: 1993
  end-page: 619
  article-title: Bcl‐2 heterodimerizes with a conserved homolog, Bax, that accelerates programmed cell death
  publication-title: Cell
– volume: 12
  start-page: 819
  year: 2000
  end-page: 827
  article-title: Differences in bcl‐2‐ and bax‐independent function in regulating apoptosis in sensory neuron populations
  publication-title: Eur. J. Neurosci.
– volume: 64
  start-page: 141
  year: 1999
  end-page: 148
  article-title: Caspase‐3‐like proteases and 6‐hydroxydopamine induced cell death
  publication-title: Brain Res. Mol. Brain Res.
– volume: 355
  start-page: 389
  year: 2000
  end-page: 394
  article-title: Mitochondrial respiratory chain disorders II: neurodegenerative disorders and nuclear gene defects
  publication-title: Lancet
– volume: 63
  start-page: 1987
  year: 1994
  end-page: 1990
  article-title: Complex I inhibitors induce dose‐dependent apoptosis in PC12 cells: relevance to Parkinson's disease
  publication-title: J. Neurochem.
– volume: 18
  start-page: 503
  year: 1999
  end-page: 510
  article-title: Ventral mesencephalic (dopaminergic) and septal cholinergic neurons
  publication-title: IBRO Handbook Series
– volume: 73
  start-page: 979
  year: 1996
  end-page: 987
  article-title: Increased M‐calpain expression in the mesencephalon of patients with Parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death?
  publication-title: Neuroscience
– volume: 270
  start-page: 96
  year: 1995
  end-page: 99
  article-title: Bax‐deficient mice with lymphoid hyperplasia and male germ cell death
  publication-title: Science
– volume: 144
  start-page: 891
  year: 1999
  end-page: 901
  article-title: Bid‐induced conformational change of Bax is responsible for mitochondrial cytochrome release during apoptosis
  publication-title: J. Cell Biol.
– volume: 97
  start-page: 2875
  year: 2000
  end-page: 2880
  article-title: Caspase‐3: a vulnerability factor and a final effector in the apoptotic death of dopaminergic neurons in Parkinson's disease
  publication-title: Proc. Natl Acad. Sci. USA
– volume: 334
  start-page: 345
  year: 1988
  end-page: 348
  article-title: Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
  publication-title: Nature
– volume: 6
  start-page: 513
  year: 2000
  end-page: 519
  article-title: Mitochondrial control of cell death
  publication-title: Nat. Med.
– volume: 139
  start-page: 1281
  year: 1997
  end-page: 1292
  article-title: Movement of Bax from the cytosol to mitochondria during apoptosis
  publication-title: J. Cell Biol.
– volume: 14
  start-page: 383
  year: 1999
  end-page: 385
  article-title: Dopaminergic neurons degenerate by apoptosis in Parkinson's disease
  publication-title: Mov. Disord.
– volume: 339
  start-page: 1130
  year: 1998
  end-page: 1143
  article-title: Parkinson's disease. Second of two parts
  publication-title: N. Engl. J. Med.
– volume: 204
  start-page: 85
  year: 1996
  end-page: 88
  article-title: Increase in Bax expression in substantia nigra following 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) treatment of mice
  publication-title: Neurosci. Lett.
– volume: 170
  start-page: 191
  year: 1994
  end-page: 194
  article-title: Apoptosis induced by 1‐methyl‐4‐phenylpyridinium ion (MPP+) in ventral mesencephalic striatal co‐culture in rat
  publication-title: Neurosci. Lett.
– ident: e_1_2_7_25_1
  doi: 10.1523/JNEUROSCI.19-04-01284.1999
– ident: e_1_2_7_34_1
  doi: 10.1016/0092-8674(93)90509-O
– ident: e_1_2_7_6_1
  doi: 10.1083/jcb.144.5.891
– ident: e_1_2_7_20_1
  doi: 10.1038/74994
– ident: e_1_2_7_24_1
  doi: 10.1016/S0092-8674(00)80434-1
– ident: e_1_2_7_32_1
  doi: 10.1016/0306-4522(96)00100-5
– ident: e_1_2_7_3_1
  doi: 10.1073/pnas.100121097
– ident: e_1_2_7_23_1
  doi: 10.1038/10556
– ident: e_1_2_7_2_1
  doi: 10.1016/s0047-6374(99)00048-2
– ident: e_1_2_7_26_1
  doi: 10.1016/0006-8993(92)91479-X
– ident: e_1_2_7_40_1
  doi: 10.1002/(sici)1097-4547(19981015)54:2<214::aid-jnr9>3.3.co;2-q
– ident: e_1_2_7_9_1
  doi: 10.1093/brain/114.5.2283
– ident: e_1_2_7_14_1
  doi: 10.1002/1531-8257(199903)14:2<383::AID-MDS1037>3.0.CO;2-F
– ident: e_1_2_7_44_1
  doi: 10.1083/jcb.139.5.1281
– ident: e_1_2_7_41_1
  doi: 10.1016/s0306-4522(96)00545-3
– ident: e_1_2_7_7_1
  doi: 10.1016/s0306-4522(98)00154-7
– ident: e_1_2_7_30_1
  doi: 10.1046/j.1460-9568.2000.00966.x
– ident: e_1_2_7_4_1
  doi: 10.1016/S0925-4439(98)00083-0
– ident: e_1_2_7_29_1
  doi: 10.1046/j.1471-4159.1999.0722074.x
– ident: e_1_2_7_5_1
  doi: 10.1016/S0896-6273(00)80173-7
– ident: e_1_2_7_42_1
  doi: 10.1016/s0304-3940(97)00837-9
– ident: e_1_2_7_11_1
  doi: 10.1073/pnas.040556597
– ident: e_1_2_7_39_1
  doi: 10.1038/17135
– ident: e_1_2_7_19_1
  doi: 10.1523/JNEUROSCI.15-10-06364.1995
– ident: e_1_2_7_22_1
  doi: 10.1016/s0140-6736(99)05226-5
– ident: e_1_2_7_37_1
  doi: 10.1016/s0306-4522(97)00640-4
– ident: e_1_2_7_16_1
  doi: 10.1073/pnas.94.14.7531
– ident: e_1_2_7_27_1
  doi: 10.1046/j.1471-4159.1996.67041633.x
– ident: e_1_2_7_13_1
  doi: 10.1038/334345a0
– ident: e_1_2_7_21_1
  doi: 10.1056/NEJM199810153391607
– ident: e_1_2_7_33_1
  doi: 10.1046/j.1471-4159.1998.70062637.x
– ident: e_1_2_7_38_1
  doi: 10.1038/sj.cdd.4400449
– ident: e_1_2_7_15_1
  doi: 10.1073/pnas.94.8.3668
– ident: e_1_2_7_17_1
  doi: 10.1002/ana.410440712
– volume: 18
  start-page: 503
  year: 1999
  ident: e_1_2_7_28_1
  article-title: Ventral mesencephalic (dopaminergic) and septal cholinergic neurons
  publication-title: IBRO Handbook Series
– ident: e_1_2_7_8_1
  doi: 10.1016/s0169-328x(98)00318-0
– ident: e_1_2_7_10_1
  doi: 10.1046/j.1471-4159.1994.63051987.x
– volume: 19
  start-page: 7476
  year: 1999
  ident: e_1_2_7_35_1
  article-title: BAX translocation is a critical event in neuronal apoptosis: regulation by neuroprotectants, BCL‐2, and caspases
  publication-title: J. Neurosci.
  doi: 10.1523/JNEUROSCI.19-17-07476.1999
– ident: e_1_2_7_43_1
  doi: 10.1038/70237
– ident: e_1_2_7_12_1
  doi: 10.1016/0304-3940(96)12323-5
– ident: e_1_2_7_18_1
  doi: 10.1126/science.270.5233.96
– ident: e_1_2_7_31_1
  doi: 10.1016/0304-3940(94)90271-2
– ident: e_1_2_7_36_1
  doi: 10.1038/sj.onc.1202590
SSID ssj0016461
Score 2.0662675
Snippet Bax is a proapoptotic member of the Bcl‐2 family of proteins. It is believed to exert its action primarily by facilitating the release of cytochrome c from the...
Bax is a proapoptotic member of the Bcl‐2 family of proteins. It is believed to exert its action primarily by facilitating the release of cytochrome c from the...
Bax is a proapoptotic member of the Bcl-2 family of proteins. It is believed to exert its action primarily by facilitating the release of cytochrome c from the...
SourceID proquest
pubmed
pascalfrancis
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1785
SubjectTerms 1-Methyl-4-phenylpyridinium - pharmacology
Adult
Aged
Animals
apoptosis
Apoptosis - physiology
Bax
bcl-2-Associated X Protein
Biological and medical sciences
Brain - metabolism
Brain - pathology
Cells, Cultured
cytochrome c
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
Dopamine - metabolism
Embryo, Mammalian
Humans
Intracellular Membranes - drug effects
Intracellular Membranes - metabolism
Lewy Bodies - metabolism
Lewy Bodies - pathology
Medical sciences
Mesencephalon - cytology
Mesencephalon - metabolism
mitochondria
Mitochondria - metabolism
MPP
Neurology
Neurons - drug effects
Neurons - metabolism
Neurons - pathology
Parkinson Disease - metabolism
Parkinson Disease - pathology
Parkinson's disease
Proto-Oncogene Proteins - metabolism
Proto-Oncogene Proteins c-bcl-2
Rats
Rats, Wistar
Reference Values
Substantia Nigra - metabolism
Substantia Nigra - pathology
Tyrosine 3-Monooxygenase - metabolism
Title Is Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease?
URI https://onlinelibrary.wiley.com/doi/abs/10.1046%2Fj.1471-4159.2001.00160.x
https://www.ncbi.nlm.nih.gov/pubmed/11259496
https://www.proquest.com/docview/17859758
https://www.proquest.com/docview/76988960
Volume 76
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3da9RAEB-kLwpitfUj1dZ9EH3Kkdwm-_Ek9bS0FfsgFvoW9isg9ZLD3EH1r3dmk1w9qVDEtyNkl8tmZvb3y878BuCV5AW6EM9T6X2dYvSbptYFJK5BBe2FKFSsrfp0Jo7Pi9OL8mLIf6JamF4fYv3BjTwjxmtycGP7LiRZVLclJ5fIf3A_JpqXT2LL5AnhyZwLktF__3mtJEUqWvlaOBwNdUjqGQ84b5poY6e6vzAdLlrdd7u4CY5uotu4PR1tw-X4YH1WyuVktbQT9_MPzcf_8-QP4cGAYtlhb3aP4E5odmD3sEEGP__BXrOYVxo_2O_A3dnYU24X7EnH3pkrZtgcIwlG3saTA7BYv4Lsn31tmFm0i2WLEzNP8JS1NfPI7OexShGvRgXOpqNbqWQ7Vq-96dhw0vT2MZwfffgyO06HLg-pKwvcBLQ0ZebrTGhky0g2tdVKeKURSE-ndWYRY0hRUD6MnPqMG-m4rHkoc-G00lbyJ7DVtE14Bswj2vIuaFtzBEqcm0wYbn3pnMIwlBUJyPGNVm6QQKdOHN-qeBRfiEiFZF7R0lKDzryKS1tdJZCvRy56GZBbjNnfMJrrgchBMawn8HI0ogpfAx3UmCa0q67KpUKeV6q_3yGFVgrJZwJPe-v7bXIktIUWCYhoQ7f-u9Xp2Yx-7f3rwOdw7zpB7wVsLb-vwj4itqU9QF88-XgQPfIXhgUvEg
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1ba9RAFD5IfaggXlovUWvnQfQpa7KTzOVJ6mLZ1nYfpIW-hbkFit1kabLQ9td7ZpJsXalQxLcQMkMyOefM9825AXzgNEMVomnMrS1jtH7jWBuHxNUJJy1jmQi5VcczNj3NDs_ys74dkM-F6epDrA7cvGYEe-0V3B9If-7dkr2WcyRAuCF7npeOQs_kEQLKh8Fd5xHSj1UtKV9HK12VDkdR7cN6BhfnXTOt7VWPF6rBZSu7fhd3AdJ1fBs2qP2ncDF8WheX8nO0bPXI3PxR9fE_ffszeNIDWbLXSd5zeOCqLdjeq5DEz6_JRxJCS8OZ_RZsToa2ctugDxryVV0RReZoTND4VtbrAAkpLG19Sc4rohb1oq1xYmI9QiV1SSyS-3lIVMS7oQhn1fhHfdZ2SGD71JDe2fTlBZzufzuZTOO-0UNs8gz3AclVntgyYRIJM_JNqaVgVkjE0uNxmWiEGZxlPiSGj21CFTeUl9TlKTNSSM3pS9io6sq9BmIRcFnjpC4pYiVKVcIU1TY3RqAlSrII-PBLC9NXQffNOC6K4I3PWGBDPC380voenWkRlra4iiBdjVx0lUDuMWZnTWpuByINRcsewe4gRQX-Bu-rUZWrl02RcoFULxd_f4IzKQTyzwhedeL32-TIaTPJImBBiO79usXhbOKv3vzrwF3YnJ4cHxVHB7Pvb-HRbbzeO9hoL5duBwFcq98HxfwFYW4yNw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1ba9RAFD5ICyqI1dZLrLXzIPqUbbIzmcuT1NWlrbqIWOhbmMlMQOomwexC66_3zCTZulKhiG9LyAybybl8X84N4KWgDFWIprGwtozR-o1jUzgkrk46ZTlnMtRWfZrxo1N2cpad9flPvham6w-x-uDmNSPYa6_gjS0P-qhkr-QC-Q_6Y0_z0lEYmTxCPLnJOHpND5C-rFpJ-TZa6apzOEpqn9UzRDiv22nNVd1rdIunVnbjLq7Do-vwNvin6RacD0_WpaWcj5YLMyp-_tH08f88-gO438NYctjJ3UO45apt2DmskMLPL8krEhJLwxf7bbgzGYbK7YA5bslbfUE0maMpQdNbWa8BJBSwIP0n3yqim7pZ1LgxsR6fkrokFqn9PJQp4tXQgrNq_a2-ZjuUr71uSR9qevMITqfvv06O4n7MQ1xkDL2AEjpLbJlwhXQZ2aYySnIrFSLp8bhMDIIMwZlPiBFjm1AtCipK6rKUF0oqI-hj2Kjqyj0FYhFu2cIpU1JESpTqhGtqbFYUEu1QwiIQwxvNi74Huh_F8T0PsXjGAxcSae6P1k_oTPNwtPlFBOlqZdP1AbnBmr01oblaiCQU7XoE-4MQ5fgafKRGV65etnkqJBK9TP79DsGVlMg-I3jSSd9vmyOjZYpHwIMM3fjv5iezif_17F8X7sPtz--m-cfj2YdduHuVrPccNhY_lm4P0dvCvAhq-QuIUzDm
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Is+Bax+a+mitochondrial+mediator+in+apoptotic+death+of+dopaminergic+neurons+in+Parkinson%27s+disease%3F&rft.jtitle=Journal+of+neurochemistry&rft.au=Hartmann%2C+Andreas&rft.au=Michel%2C+Patrick+P.&rft.au=Troadec%2C+Jean%E2%80%90Denis&rft.au=Mouatt%E2%80%90Prigent%2C+Annick&rft.date=2001-03-01&rft.pub=Blackwell+Science+Ltd&rft.issn=0022-3042&rft.eissn=1471-4159&rft.volume=76&rft.issue=6&rft.spage=1785&rft.epage=1793&rft_id=info:doi/10.1046%2Fj.1471-4159.2001.00160.x&rft.externalDBID=10.1046%252Fj.1471-4159.2001.00160.x&rft.externalDocID=JNC0160
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-3042&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-3042&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-3042&client=summon